Matrix Moments, by Matrix Partners India, is a podcast series dedicated to the founders, startups and all those within the ecosystem, through candid conversations on what we think it really takes to survive in this wild, wild startup world. In a world where we are endlessly engulfed with information in all its forms and sizes, this is our attempt to create, curate and bring to you the insights and reflections that we have had the luxury of having learned the hard way, through all the years s ...
743: Mo Khan of Open Orphan discusses £7.2m contract with an existing top 5 global pharmaceutical company
Manage episode 331558536 series 2936804
بواسطة Vox Markets Podcast، اكتشفه Player FM ومجتمعنا ـ حقوق الطبع والنشر مملوكة للناشر وليس لـPlayer FM، والصوت يبث مباشرة من خوادمه. اضغط زر الاشتراك لمتابعة التحديثات في Player FM، أو ألصق رابط التغذية الراجعة في أي تطبيق بودكاست آخر.
Mo Khan CEO of Open Orphan #ORPH discusses the £7.2m contract signed with an existing top 5 global pharmaceutical company to test its orally administered antiviral product, using hVIVO's respiratory syncytial virus Human Challenge Study Model.
The Phase 2a double-blinded placebo-controlled human challenge study will take place at the Company's specialist quarantine facilities in Whitechapel and will evaluate the safety and efficacy profile of the antiviral against RSV. The study will commence in June 2022, with the revenue being recognised in 2022 and 2023. As part of the study, hVIVO will recruit healthy volunteers via the Company's dedicated volunteer recruitment arm, FluCamp.
The client's antiviral is presently in Phase III clinical trials for another infectious disease indication and the client will use human challenge to assess the efficacy of their antiviral drug candidate against RSV quickly and efficiently, highlighting the value that human challenge studies can bring within the drug development process. The repeat business from this top 5 global pharmaceutical company underlines the Company's world leading expertise and its ability to attract additional contracts from its existing Big Pharma clients.
To read the Full RNS click HERE